- Home
- DAY vs RDY Comparison
DAY vs RDY Comparison
Compare DAY & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAY
- RDY
- Stock Information
- Founded
- DAY 1992
- RDY 1984
- Country
- DAY United States
- RDY India
- Employees
- DAY N/A
- RDY N/A
- Industry
- DAY
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- DAY
- RDY Health Care
- Exchange
- DAY NYSE
- RDY Nasdaq
- Market Cap
- DAY 11.8B
- RDY 13.1B
- IPO Year
- DAY 2018
- RDY N/A
- Fundamental
- Price
- DAY $78.23
- RDY $13.99
- Analyst Decision
- DAY Buy
- RDY Buy
- Analyst Count
- DAY 9
- RDY 1
- Target Price
- DAY $81.56
- RDY $17.00
- AVG Volume (30 Days)
- DAY 2.0M
- RDY 770.6K
- Earning Date
- DAY 10-30-2024
- RDY 11-05-2024
- Dividend Yield
- DAY N/A
- RDY 4.04%
- EPS Growth
- DAY 1200.52
- RDY 4.63
- EPS
- DAY 0.34
- RDY 0.76
- Revenue
- DAY $1,694,500,000.00
- RDY $3,579,112,656.00
- Revenue This Year
- DAY $16.80
- RDY $13.39
- Revenue Next Year
- DAY $12.22
- RDY $8.35
- P/E Ratio
- DAY $225.68
- RDY $18.83
- Revenue Growth
- DAY 16.85
- RDY 12.37
- 52 Week Low
- DAY $47.08
- RDY $12.90
- 52 Week High
- DAY $81.33
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- DAY 65.30
- RDY 32.92
- Support Level
- DAY $72.44
- RDY $13.97
- Resistance Level
- DAY $81.33
- RDY $14.40
- Average True Range (ATR)
- DAY 2.22
- RDY 0.27
- MACD
- DAY -0.66
- RDY -0.04
- Stochastic Oscillator
- DAY 48.93
- RDY 9.72
About DAY DAYFORCE INC
Dayforce provides payroll and human capital management solutions targeting clients with 100-100,000 employees. Following the 2012 acquisition of Dayforce, Dayforce pivoted away from its legacy on-premises Bureau business to become a cloud HCM provider. As of fiscal 2022, about 80% of group revenue was derived from the flagship Dayforce platform geared toward enterprise clients. The remaining revenue is about evenly split between cloud platform Powerpay, targeting small businesses in Canada, and legacy Bureau products.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.